Molecularly Imprinted Nanogels Acquire Stealth In Situ by Cloaking Themselves with Native Dysopsonic Proteins

Protein corona formation was regulated on the surface in vivo by molecular imprinting to enable polymeric nanogels to acquire stealth upon intravenous administration. Albumin, the most abundant protein in blood, was selected as a distinct protein component of protein corona for preparing molecularly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Angewandte Chemie 2017-06, Vol.129 (25), p.7194-7198
Hauptverfasser: Takeuchi, Toshifumi, Kitayama, Yukiya, Sasao, Reo, Yamada, Takuya, Toh, Kazuko, Matsumoto, Yu, Kataoka, Kazunori
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Protein corona formation was regulated on the surface in vivo by molecular imprinting to enable polymeric nanogels to acquire stealth upon intravenous administration. Albumin, the most abundant protein in blood, was selected as a distinct protein component of protein corona for preparing molecularly imprinted nanogels (MIP‐NGs) to form an albumin‐rich protein corona. Intravital fluorescence resonance energy transfer imaging of rhodamine‐labeled albumin and fluorescein‐conjugated MIP‐NGs showed that albumin was captured by MIP‐NGs immediately after injection, forming an albumin‐rich protein corona. MIP‐NGs circulated in the blood longer than those of non‐albumin‐imprinted nanogels, with almost no retention in liver tissue. MIP‐NGs also passively accumulated in tumor tissue. These data suggest that this strategy, based on regulation of the protein corona in vivo, may significantly influence the development of drug nanocarriers for cancer therapy. Durch molekulares Prägen wurden Polymernanogele (MIP‐NGs) mit einer Proteinschale mit hohem Anteil an humanem Serumalbumin versehen. Dadurch resultierten Nanotransporter mit längerer Blutzirkulationsdauer, die praktisch nicht von Lebergewebe zurückgehalten werden. MIP‐NGs akkumulieren außerdem passiv in Tumorgewebe. Diese Eigenschaften werden in situ ohne Serumalbumin‐Vorbehandlung erzeugt, was toxische Nebenwirkungen einschränkt.
ISSN:0044-8249
1521-3757
DOI:10.1002/ange.201700647